BTLA promoter hypomethylation correlates with enhanced immune cell infiltration, favorable prognosis, and immunotherapy response in melanoma
Background Immune checkpoint blockade (ICB)-based immunotherapy has significantly improved survival in advanced melanoma. However, many patients exhibit resistance to these therapies. This study examines the impact of BTLA promoter methylation on its expression, immune cell infiltration, and clinica...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2025-03-01
|
| Seri Bilgileri: | Journal for ImmunoTherapy of Cancer |
| Online Erişim: | https://jitc.bmj.com/content/13/3/e009841.full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|